Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Davis

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2017
Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic OssificationShailesh Agarwal, Shawn J Loder, Christopher Breuler, et al.
Neuro-Oncology|January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyJames Schuster, Rose K Lai, Lawrence D Recht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast CancerDenise A Yardley, Robert Weaver, Michelle E Melisko, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
Scientific Reports|March 4, 2024
The influence of microbial colonization on inflammatory versus pro-healing trajectories in combat extremity woundsSeth A Schobel, Eric R Gann, Desiree Unselt, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2017
Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic OssificationShailesh Agarwal, Shawn J Loder, Christopher Breuler, et al.
Neuro-Oncology|January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyJames Schuster, Rose K Lai, Lawrence D Recht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast CancerDenise A Yardley, Robert Weaver, Michelle E Melisko, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaGiao Q Phan, James C Yang, Richard M Sherry, et al.
Scientific Reports|March 4, 2024
The influence of microbial colonization on inflammatory versus pro-healing trajectories in combat extremity woundsSeth A Schobel, Eric R Gann, Desiree Unselt, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 12